The presence of neoantigens and TAA is also necessary for awaking exhausted tumor-infiltrating lymphocytes (TIL) upon treatment with immune checkpoint inhibitors (ICI) such as anti-CTLA4 or anti-PD1/PDL1 antibodies (179–183). The gene discussed is CD274; the disease is neoplasm.